The Scientist

» pharmaceuticals

Most Recent

With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.

0 Comments

image: Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion

Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion

By | January 10, 2017

The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.

0 Comments

image: Drug Approval Timeline Same as 20 Years Ago

Drug Approval Timeline Same as 20 Years Ago

By | January 9, 2017

A report finds that new medications still take about 12 years to go from patent to patient.

0 Comments

image: European Drug Regulator Releases Clinical Trial Data

European Drug Regulator Releases Clinical Trial Data

By | October 21, 2016

In the initial steps of a campaign to make clinical reports publicly available, the European Medicines Agency has published data on two recently approved drugs.

0 Comments

image: NYU Halts Studies, Suspends Investigator

NYU Halts Studies, Suspends Investigator

By | June 28, 2016

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

2 Comments

image: Another Drug Price Hike

Another Drug Price Hike

By | March 28, 2016

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

0 Comments

image: Abbott Acquires Diagnostics Firm

Abbott Acquires Diagnostics Firm

By | February 2, 2016

In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.

0 Comments

image: Shire to Buy Baxalta for $32 Billion

Shire to Buy Baxalta for $32 Billion

By | January 12, 2016

The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.

0 Comments

image: Thermo Fisher to Acquire Affymetrix

Thermo Fisher to Acquire Affymetrix

By | January 11, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Bayer Enters CRISPR Field

Bayer Enters CRISPR Field

By | December 22, 2015

The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.

0 Comments

Popular Now

  1. A Coral to Outlast Climate Change
  2. Science Celebrities: Where Are the Women?
  3. First In Vivo Human Genome Editing to Be Tested in New Clinical Trial
  4. Understanding Body Ownership and Agency
AAAS